Real-World Study Confirms Inotuzumab Ozogamicin Efficacy in Indian Patients with Relapsed/Refractory B-Cell ALL
核心洞察
A multicenter retrospective study of 32 Indian patients with relapsed/refractory B-cell ALL treated with inotuzumab ozogamicin achieved a 59.4% complete remission rate, with 94.7% of responders achieving minimal residual disease negativity.
The study demonstrated comparable efficacy to international trials despite patients receiving treatment later in their disease course, with most responses occurring after a median of two cycles.
Veno-occlusive disease occurred in 22% of patients, primarily after hematopoietic stem cell transplantation, representing a higher rate than previously reported in clinical trials.
A multicenter retrospective analysis of inotuzumab ozogamicin (InO) treatment in Indian patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) has demonstrated significant clinical efficacy, achieving complete remission rates comparable to international clinical trials despite real-world treatment challenges.
The study, conducted across five oncology centers in India, evaluated 32 adult patients with CD22 (搜索)-positive relapsed/refractory B-cell ALL who received InO monotherapy. Patients had a median age of 37.4 years, with 28 patients experiencing disease relapse and four showing refractory disease to previous chemotherapy regimens.
Treatment Outcomes and Response Rates
The primary endpoint analysis revealed that 59.4% of patients (19/32) achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), with 18 patients achieving CR and one achieving CRi. Most responses occurred after a median of two InO cycles, demonstrating the drug's rapid therapeutic effect.
Among patients who achieved remission, 94.7% (18/19) attained minimal residual disease (MRD) negativity, a critical prognostic indicator for long-term survival in B-cell ALL. The study found that CR/CRi rates were higher in patients receiving InO as first (60%) or second (61%) salvage therapy compared to later treatment lines (50%).
Disease burden at baseline did not significantly influence response rates, with comparable CR/CRi rates observed in patients with less than 50% bone marrow blasts (62.5%) versus those with greater than 50% blasts (56.25%).
Survival and Transplantation Outcomes
The median duration of remission was 6 months among patients who achieved CR/CRi, while the median relapse-free survival was 7.0 months (95% CI: 6.1-8.9 months). Overall survival rates were 46.9% at 6 months and 28.1% at 12 months, with a median overall survival of 6 months (95% CI: 4.5-7.5).
Among the 19 patients who achieved remission, 47.4% (9/19) proceeded to hematopoietic stem cell transplantation (HSCT), with 66.7% (6/9) undergoing transplantation after a single cycle of InO treatment.
Safety Profile and Adverse Events
The safety analysis revealed that veno-occlusive disease (VOD) occurred in 22% of patients (7/32), representing a higher incidence than the 11% reported in the pivotal INO-VATE trial. Notably, 71.4% of VOD cases (5/7) developed after HSCT, suggesting increased risk in the post-transplant setting.
Grade 3/4 hepatotoxicity affected 37.5% of patients, while hematologic toxicities were the most frequent adverse events, occurring in 87.5% of the cohort. The researchers attributed the higher rates of hepatic complications to the high prevalence of steatohepatitis in India, which may predispose patients to increased hepatotoxicity with InO treatment.
Comparison with International Data
The study's findings align closely with results from the global phase 3 INO-VATE ALL study, which reported CR/CRi rates of 73.8% versus 29.4% for standard chemotherapy (p < 0.001) and MRD-negativity rates of 78.4% versus 28.1% (p < 0.001). The slightly lower remission rate in the Indian cohort was attributed to several factors, including smaller sample size, later initiation of InO therapy due to logistic constraints, and a more heavily pre-treated patient population.
Clinical Implications and Study Limitations
The research provides valuable real-world evidence for InO use in Indian clinical practice, where management of relapsed/refractory B-cell ALL is often complicated by delayed diagnosis, financial constraints, and limited access to novel agents. InO was introduced in India through an early access program in 2017 and became commercially available in 2020.
Study limitations include the inherent constraints of a retrospective design, inconsistency in reporting and follow-up resulting in missing data, potential selection bias, and limited sample size restricting subgroup analysis. Despite these limitations, the study represents important real-world evidence supporting InO's effectiveness in the Indian healthcare setting.
The mortality analysis revealed that disease progression was the major cause of death (60.8% of 17 total deaths), followed by septic shock (11.8%). VOD-related complications, including multi-organ failure and VOD-associated pneumonia, each accounted for 5.9% of deaths, both occurring in patients with HSCT history.
The researchers concluded that InO monotherapy represents an effective and relatively safe treatment option for adults with CD22 (搜索)-positive relapsed/refractory B-cell ALL in real-world clinical practice, while emphasizing the need for larger prospective studies to better characterize long-term outcomes.